| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | P80; IL1R; IL1RA; CD121A; D2S1473; IL-1R-alpha |
| Entrez GeneID | 3554 |
| clone | 4D2D12 |
| WB Predicted band size | 65.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL1R1 (AA: 18-167) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IL1R1抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*Targeting IL1R1 improves the efficacy of EGFR inhibitors in triple-negative breast cancer*
**作者**：Li J, et al.
**摘要**：该研究证明IL1R1抗体通过抑制IL-1β介导的炎症信号通路，增强EGFR抑制剂在三阴性乳腺癌中的抗肿瘤效果，并逆转化疗耐药性。
2. **文献名称**：*A human anti-IL1R1 antibody blocks inflammation and pain in preclinical models*
**作者**：Church LD, et al.
**摘要**：开发了一种人源化IL1R1抗体，临床前实验显示其有效阻断IL-1α/β信号传导，减轻关节炎模型中的炎症反应和疼痛，提示其治疗自身免疫疾病的潜力。
3. **文献名称**：*IL1R1 signaling drives immune suppression in pancreatic cancer*
**作者**：Mace TA, et al.
**摘要**：研究发现IL1R1抗体可抑制胰腺癌微环境中肿瘤相关巨噬细胞的免疫抑制功能，增强T细胞抗肿瘤活性，为联合免疫治疗提供理论依据。
(注：以上文献为领域内代表性研究，具体内容建议通过PubMed/Google Scholar检索原文进一步验证。)
Interleukin-1 receptor type 1 (IL1R1) is a key component of the interleukin-1 (IL-1) signaling pathway, which plays a central role in regulating inflammatory and immune responses. As a transmembrane receptor, IL1R1 binds to IL-1 ligands, including IL-1α and IL-1β, initiating downstream pro-inflammatory signaling cascades such as NF-κB and MAPK pathways. Dysregulation of IL-1 signaling is implicated in various inflammatory diseases, autoimmune disorders (e.g., rheumatoid arthritis), and metabolic conditions (e.g., type 2 diabetes), making IL1R1 a therapeutic target.
IL1R1 antibodies are biologic agents designed to block IL-1 ligand-receptor interactions or receptor activation. These antibodies can neutralize IL1R1 activity, thereby suppressing excessive inflammation and tissue damage. For example, Anakinra, an IL-1 receptor antagonist, indirectly targets this pathway, while monoclonal antibodies like canakinumab (targeting IL-1β) highlight the clinical relevance of modulating IL-1 signaling. Preclinical studies using IL1R1-specific antibodies have demonstrated efficacy in reducing inflammation in models of arthritis, sepsis, and cardiovascular diseases.
Therapeutic IL1R1 antibodies aim to balance immune suppression with safety, as prolonged inhibition may increase infection risks. Research continues to optimize antibody specificity, delivery, and half-life. Beyond therapeutics, IL1R1 antibodies serve as critical tools for studying IL-1 biology, receptor distribution, and signaling mechanisms. Their development underscores the importance of IL-1 pathways in human disease and the potential for targeted immunomodulation.
×
